Browsing Tag
AACR
5 posts
AACR 2026: Precision Biologics says it found a new weak spot in AML for CAR-NK therapy
Precision Biologics has revealed a new AML CAR-NK target at AACR 2026. Read why truncated O-glycans could matter for future leukemia therapy.
April 17, 2026
Avacta (AIM: AVCT): First patient dosed in FOCUS-01 with three data catalysts lined up across 2026
Avacta (AIM: AVCT) dosed the first FOCUS-01 patient in March 2026. Three catalysts follow: AACR April 21, AVA6000 H1 update, AVA6103 late H2 data. Full retail investor roadmap inside.
April 14, 2026
Ovarian cancer treatment options, survival rates, and the newest FDA approvals in 2026
Ovarian cancer affects 21,000 US women annually. This guide covers symptoms, staging, survival rates, BRCA risk, and the newest FDA-approved treatments through early 2026.
April 11, 2026
Avacta (AVCT) at AACR 2026: What the San Diego data presentations actually mean if you’re holding shares through the trial
Avacta Therapeutics (AIM: AVCT) is presenting two posters at AACR 2026 in San Diego. Here is what investors need to understand about conference data versus clinical trial readouts and which milestones actually move the stock.
April 7, 2026
How CLD-401 and RedTail may redefine tumor-localized immune activation in solid tumors
Can RedTail and CLD-401 change solid tumor immunotherapy? Read why Calidi Biotherapeutics, Inc.’s next milestones could reshape the CLDI story.
April 3, 2026